Table 1.
Percentages of consensus scores ranking the quality of evidence of the highest-rated routinely used fractionation schedules compared with the recommended COVID-era schedules for curative and palliative treatments
| ASTRO quality of evidence | Curative |
Curative, cutaneous |
Palliative, disease-site specific |
Palliative, general |
||||
|---|---|---|---|---|---|---|---|---|
| Highest quality | COVID era (N = 146) | Highest quality | COVID era (N = 14) | Highest quality | COVID era (N = 65) | Highest quality | COVID era (N = 9) | |
| High | 51.4% | 4.8% | 0% | 0% | 16.1% | 1.5% | 55.6% | 33.3% |
| Moderate | 33.3% | 17.1% | 0% | 0% | 5.4% | 13.9% | 11.1% | 33.3% |
| Low | 9.7% | 28.8% | 83.3% | 83.3% | 39.3% | 21.5% | 33.3% | 22.2% |
| Opinion | 5.6% | 49.3% | 16.7% | 16.7% | 39.3% | 63.1% | 0% | 11.1% |
Abbreviations: ASTRO = American Society of Radiation Oncology; N = number of recommended dose fractionation schedules.